The global blood group typing market size is estimated to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to wide application of blood group testing in neonatal evaluation and forensic laboratories, increasing government initiative to promote blood donation, and development of advance technologies for blood group typing devices.
Blood is made up of red blood cells (RBCs), white blood cells (WBCs), and platelets that are collectively known as blood plasma. Blood group testing is carried out by characterization of antibodies and antigens exist in circulatory system in the body. According to ABO system, the blood groups are primarily categorized as A, B, O, and its derivative groups. Among these, AB blood group followed by Rh system is known for positive or negative blood group based on antigen present. Blood group typing is compulsory process before blood transfusion to estimate blood compatibility between the donor and recipient. For testing of blood group, the red blood cells are centrifuge with various antibody samples. For instance, if the solution containing anti-B antibodies and a person with B-antigen, then the resulting blood group is B due to both the antibody and antigen clump with each other. Blood group typing is very important during pregnancy for reducing risk of anemia in infants.
One key aspect for the growth of the market is due to a vast arrangement of blood donation programs globally with the participation from several non-governmental organizations. Various regulatory agencies across regions are actively engaged in advancement and execution of programs for accessibility improvement to secure blood transfusion. Additionally, several policies are enforced by governments to prevent bioterrorism and illegal operations of blood banks. These blood donation campaigns, increasing number of blood banks, and favorable government policies further increase demand of blood testing kits are key factors offering market growth.
The report on the global blood group typing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Blood Group Typing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Products (Consumables, Instruments, and Services), Techniques (PCR-based and Microarray Techniques, Assay-based Techniques, Massively Parallel Sequencing Techniques, and Others), Test Types (Antibody Screening, HLA Typing, Cross-matching Tests, ABO Blood Tests, and Antigen Typing) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Grifols S.A.; Merck KGaA; Bio-Rad Laboratories, Inc.; Immucor, Inc.; Novacyt Group; Danaher Corporation; Agena Bioscience, Inc.; Ortho Clinical diagnostics; Quotient Limited, and AXO Science |
Consumables segment is expected to grow at a rapid pace
Based on products, the global blood group typing market is divided into consumables, instruments, and services. The consumables segment constituted a key share of the market in terms of revenue and is expected to expand at a rapid pace during the forecast period. The segment growth is attributed to rising number of surgeries, organ replacements, as well as wide utilization of serological fluids and reagents in clinical laboratories. Increasing blood donation programs that result in rising blood specimen collection and emerging use of molecular diagnosis testing kits and reagents that lessen testing time are the major factors anticipated to boost segment growth in the upcoming years.
PCR-based & microarray techniques segment to hold a dominant share
On the basis of techniques, the market is classified into PCR-based & microarray techniques, assay-based techniques, massively parallel sequencing techniques, and others. The PCR-based & microarray technique segment is estimated to register a significant CAGR during the forecast period from 2021-2028. The growth of the segment is attributed to rising research collaborations by key players mainly concentrated on antibody-antigen interaction and rising incidence of chronic diseases namely sickle cell anemia, aplastic anemia, traumatic injuries, and leukemia. Furthermore, rising utilization of PCR-based diagnosis for detection of infrequent blood group type along with enhanced awareness of microarray-based technique for blood donation are the factors contributing to the market growth.
North America is projected to account for a key share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2020 and is estimated to account for a key market share during the forecast period due to rising number of blood transfusion during pregnancy and in neonatal testing along with the increasing research activities by key market players. On the other hand, Asia pacific is expected to register a robust CAGR during the forecast period owing to increasing incidence of chronic disorders that require blood group detection and transfusion. Increasing prevalence of contagious diseases, high incidence of highway accidents, and rising incidence of traumatic injuries in the region are the factors that expected to the regional market expansion.
Some of the major market players competing in the market are Grifols S.A.; Merck KGaA; Bio-Rad Laboratories, Inc.; Immucor, Inc; Novacyt Group; Danaher Corporation; Agena Bioscience, Inc.; Ortho Clinical diagnostics; Quotient Limited; and AXO Science. Many of these key players are actively investing in R&D to develop novel blood typing technologies to attain business augmentation that contributed to market growth. Several of these companies are actively engaged in various market strategies such as product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base globally.
In November 2016, Immucor inc. developed method for diagnosis of sickle cell-like characteristics in blood donor. In October 2018, Grifols S.A. launched ID core XT molecular diagnostic test that employed for detection of RBCs in blood stream.
Some other reports from this category!